F2

Zealand Pharma Announces Financial Results for the Full Year 2023

Retrieved on: 
Tuesday, February 27, 2024

In parallel, Zealand is planning a Phase 2b trial of petrelintide planned for initiation in the second half of 2024.

Key Points: 
  • In parallel, Zealand is planning a Phase 2b trial of petrelintide planned for initiation in the second half of 2024.
  • In February 2024, Boehringer Ingelheim and Zealand Pharma announced positive results from the Phase 2 trial of survodutide in metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH).
  • In December 2023, Zealand submitted an NDA to the U.S. FDA for the treatment of adult patients with SBS dependent on parenteral support.
  • A recording of the event will be available following the call on the Investor section of Zealand’s website at https://www.zealandpharma.com/events/ .

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024

Royalties for the fourth quarter of 2023 were $22.5 million, compared with $22.0 million for the same period in 2022.

Key Points: 
  • Royalties for the fourth quarter of 2023 were $22.5 million, compared with $22.0 million for the same period in 2022.
  • Costs of Captisol sales were $1.6 million for the fourth quarter of 2023, compared with $21.6 million for the same period in 2022, with the decrease due to lower total Captisol sales during the fourth quarter of 2023 and $9.8 million in accelerated depreciation on Captisol manufacturing equipment during the fourth quarter of 2022.
  • Amortization of intangibles was $8.3 million for the fourth quarter of 2023, compared with $8.5 million for the same period in 2022.
  • Travere also announced fourth quarter 2023 results reporting that it received 459 new patient start forms for FILSPARI in the fourth quarter of 2023 and net product sales of $14.9 million for the fourth quarter.

INNO Golf Carts Introduces the Revolutionary INNO-F2 at PGA Show 2024

Retrieved on: 
Monday, January 22, 2024

PALO ALTO, Calif., Jan. 22, 2024 /PRNewswire/ -- INNO Golf Carts, a division of INNOXONE, is once again at the forefront of innovation in the golf cart industry with the launch of its latest model, the INNO-F2, at the PGA Show 2024.

Key Points: 
  • PALO ALTO, Calif., Jan. 22, 2024 /PRNewswire/ -- INNO Golf Carts, a division of INNOXONE, is once again at the forefront of innovation in the golf cart industry with the launch of its latest model, the INNO-F2, at the PGA Show 2024.
  • This choice further underscores INNO Golf Cart's commitment to providing a customizable and unique golfing experience.
  • INNO Golf Carts' approach to design and innovation reflects a broader trend in the golf industry towards personalization and technological integration.
  • The INNO-F2's debut is a pivotal moment for INNO Golf Carts, marking the company's continued evolution and its commitment to excellence in the golf cart industry.

Alienware Redesigns m16 R2 with Stealth Mode - Supercharges x16 R2, m18 R2

Retrieved on: 
Monday, January 8, 2024

Meet Alienware's latest product portfolio:

Key Points: 
  • Meet Alienware's latest product portfolio:
    Three new gaming notebooks debut — the redesigned Alienware m16 R2, the ultra-premium x16 R2, and our performance juggernaut, the m18 R2.
  • Meet the m16 R2, a redesigned gaming laptop that prioritizes performance, flexibility and portability, while preserving the Alienware advantages our customers have come to love.
  • The refined Alienware x16 R2 fortifies this status with faster performance, improved cooling and greater future readiness.
  • x Latest generation systems include: m16 R2, m18 R2, x16 R2 and R16, as well as the generation prior: x14 R2, x16, & m18
    View original content to download multimedia: https://www.prnewswire.com/news-releases/alienware-redesigns-m16-r2-with...

GOTRAX Announces Upgraded Versions of Folding Electric Bikes

Retrieved on: 
Saturday, January 6, 2024

DALLAS, Jan. 6, 2024 /PRNewswire/ -- GOTRAX, a leading brand in the market for personal electric vehicles, is releasing upgraded versions of its popular F1 and F2 models of folding electric bikes. Since their launch, these e-bikes have served as cutting-edge and versatile additions to the GOTRAX e-bike lineup, and with the release of their updated designs, GOTRAX looks to further raise its standard for quality in the e-bike market.

Key Points: 
  • DALLAS, Jan. 6, 2024 /PRNewswire/ -- GOTRAX , a leading brand in the market for personal electric vehicles, is releasing upgraded versions of its popular F1 and F2 models of folding electric bikes.
  • The F1 V2 and F2 V2 maintain the folding frames and wide tires that made their predecessors so beloved among riders.
  • GOTRAX hopes that riders will make the most of these new and improved versions of the F1 and F2 to revolutionize their daily transportation.
  • Since 2017, the Dallas-based company has been producing innovative personal electric vehicles, specializing in solutions for daily commuting and transportation.

Osino Drills 61m @ 2.4 G/T Au and 20m @ 5.60g/T Au in Step-Out Drilling at Eureka Gold Discovery, Namibia

Retrieved on: 
Tuesday, November 14, 2023

VANCOUVER, British Columbia, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Osino Resources Corp. (TSXV:OSI) (NSX:OSN) (FSE:RSR1) (OTCQX:OSIIF) ("Osino” or “the Company”) is pleased to provide an update on the Phase 2 drill program at the Eureka Project (“Eureka” or “the Project”). This current drill program is aimed at further definitng and expanding the Eureka godl discovery announced in the news release dated 9th August 2023.

Key Points: 
  • Results from the previous round of Eureka drilling include:
    ORD005: 47m @ 5.92g/t Au (144 – 191m) incl.
  • 27m @ 8.69g/t Au and 3m @ 13g/t Au
    ORD001: 38m@ 1.67g/t Au (43 – 81m) incl.
  • This current drill program is aimed at further definitng and expanding the Eureka godl discovery announced in the news release dated 9th August 2023.
  • This will better define the five magnetic targets outlined from the regional magnetics to date and hopefully identify further targets.

89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023

Retrieved on: 
Sunday, November 12, 2023

SAN FRANCISCO, Nov. 12, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced additional data from a post-hoc analysis of the ENLIVEN Phase 2b trial evaluating treatment with pegozafermin in a subgroup of patients with F4 NASH. These data were featured in an oral presentation during the AASLD The Liver Meeting®, being held in Boston, Massachusetts.

Key Points: 
  • These data were featured in an oral presentation during the AASLD The Liver Meeting®, being held in Boston, Massachusetts.
  • “Patients with NASH and compensated cirrhosis face a critical imperative to mitigate the risk of decompensation, necessitating therapies that halt or even reverse the progression of fibrosis,” Dr. Hank Mansbach, Chief Medical Officer of 89bio commented.
  • “While the cohort of F4 patients in ENLIVEN was relatively small, we were encouraged by data suggesting that pegozafermin could potentially provide benefits to these patients by addressing both liver pathology and the metabolic irregularities that may contribute to the disease.
  • Treatment with pegozafermin led to clinically meaningful improvements in liver specific biomarkers of stiffness and fibrosis (Pro-C3, FAST, VCTE, FIB-4), inflammation (ALT and AST), and other key non-invasive markers.

Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023

Retrieved on: 
Monday, November 13, 2023

SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of new results from the ongoing Phase 2b clinical trial of VK2809, the company's novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). The latest findings from the VOYAGE study were featured in a late breaking poster presentation at the Liver Meeting® 2023, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), which is being held November 10-14, 2023, in Boston.

Key Points: 
  • The latest findings from the VOYAGE study were featured in a late breaking poster presentation at the Liver Meeting® 2023, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), which is being held November 10-14, 2023, in Boston.
  • As previously reported, the VOYAGE study successfully achieved its primary endpoint, with patients receiving VK2809 experiencing statistically significant reductions in liver fat content from baseline to Week 12 as compared with placebo.
  • Newly reported findings demonstrated robust and comparable liver fat reductions among patients with or without type 2 diabetes, as well as patients with either F2 or F3 fibrosis.
  • The median relative reduction from baseline in liver fat ranged from 38% to 55% for patients receiving VK2809.

Segway-Ninebot Hosts “Golden Scooter” Scavenger Hunt in Downtown Los Angeles

Retrieved on: 
Thursday, November 9, 2023

Best of luck to everyone!”

Key Points: 
  • Best of luck to everyone!”
    The Segway-Ninebot KickScooter F2 is the ultimate scooter for the everyday commuter.
  • The F2 hits maximum speeds of 18 mph and a theoretical range of 25 miles to get riders where they need to go.
  • With Apple “Find My” capabilities, upgraded power, larger battery capacity, Traction Control System, and integrated turn indicators, riders enjoy a high-quality and safer ride.
  • To learn more and be part of the scavenger hunt, participants can register online here by 11:59 PM on Thursday, November 16th.

EnCompass receives FDA conditional IDE approval to commence a US pilot study of its F2 cerebral embolic protection (CEP) system in patients undergoing transcatheter aortic valve replacement (TAVR)

Retrieved on: 
Wednesday, September 27, 2023

All cardiovascular procedures cause the release of particulate debris (calcium, vessel wall, blood clot) and air bubbles, called emboli.

Key Points: 
  • All cardiovascular procedures cause the release of particulate debris (calcium, vessel wall, blood clot) and air bubbles, called emboli.
  • During the TAVR procedure, 360-degree wall apposition of the F2 filter in the aortic arch is designed to prevent migration.
  • Because the F2 filter is attached to a self-expanding nitinol stent, it is easy to insert, deploy, and retrieve.
  • In September 2023, a similar pilot study began in Australia and now with FDA conditional IDE approval, EnCompass plans to commence its first US pilot study.